Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 15 min 38 sec ago

Hansen Medical's Magellan(TM) Robotic System to Be Featured in Three Live Cases at 26th Annual International Symposium on Endovascular Therapy

Mon, 01/20/2014 - 15:29
MOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in Intravascular Robotics, today announced that Dr. Barry Katzen, founder and Medical Director of Baptist Cardiac & Vascular Institute (Baptist...
Devices, Interventional
Hansen Medical, Magellan Robotic System, Sensei-X, Robotic Catheter

Medtronic CoreValve(R) System Obtains Early FDA Approval on Exceptional Clinical Performance

Fri, 01/17/2014 - 16:23
Self-Expanding Aortic Valve Serves Broad Spectrum of Potential Transcatheter Aortic Valve Replacement (TAVR) Patients Who Are Unable to Undergo Surgery MINNEAPOLIS - Jan. 17, 2014 --(Healthcare Sales & Marketing Network)--Medtronic, Inc. (MDT) today ann...
Devices, Interventional Cardiology, FDA
Medtronic, CoreValve, Transcatheter Aortic Valve, heart valve

European Commission Grants Marketing Authorization for Gilead’s Sovaldi(R) (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Fri, 01/17/2014 - 13:47
Sovaldi Approved For Use in Genotypes 1-6 High Cure Rates and Shortened, 12-Week Course of Therapy for Treatment-Naïve Patients First All-Oral Treatment Option for Patients Who Cannot Take Interferon First Regimen for Patients Awaiting Liver...
Biopharmaceuticals, Regulatory
Gilead Sciences, Sovaldi, sofosbuvir, hepatitis C virus

Organogenesis Inc. Announces Acquisition of Dermagraft(R) from Shire

Fri, 01/17/2014 - 13:40
Product Acquisition Solidifies Organogenesis Position as Industry Leader CANTON, Mass., Jan. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it ha...
Devices, Wound Care, Acquisitions
Organogenesis, Shire plc, Dermagraft

Shire Executes Agreement to Divest DERMAGRAFT(R)

Fri, 01/17/2014 - 13:34
DUBLIN, January 17, 2014 -- (Healthcare Sales & Marketing Network) --Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, today announced that it has entered into a definitive agreement pursuant to which it has sold its DERM...
Devices, Wound Care, Acquisitions
Shire plc, Organogenesis, DERMAGRAFT

Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America

Fri, 01/17/2014 - 13:27
Nicox further expands North American diagnostic portfolio with access to the RetnaGene AMD test, a genetic laboratory-developed test to predict the risk of progressing to late-stage or "wet" age-related macular degeneration (AMD) SOPHIA ANTIPO...
Diagnostics, Ophthalmology, Licensing
Sequenom, Nicox, macular degeneration, RetnaGene

MEDITE Signs Exclusive Marketing and Distribution Agreement With Medline

Thu, 01/16/2014 - 15:35
Medline Named Exclusive U.S. and Canada Distributor for MEDITE's Best-in-Class Histology Systems and Related Consumable Products ORLANDO, FL--(Healthcare Sales & Marketing Network) - MEDITE Inc., a leading developer and manufacturer of innovative, high-...
Diagnostics, Distribution
MEDITE, CytoCore, Medline Industries

CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development

Thu, 01/16/2014 - 15:31
New position to support global Phase 3 clinical trial with aldoxorubicin in soft tissue sarcomas LOS ANGELES--(Healthcare Sales & Marketing Network)--CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncolog...
Biopharmaceuticals, Oncology, Personnel
CytRx, Aldoxorubicin, Soft Tissue Sarcoma

BioSyent Announces Appointment of New Director

Thu, 01/16/2014 - 15:28
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - The Board of Directors of BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce the appointment of Stephen Wilton to the Company's Board. Mr. Wilton brings to BioSyent ove...
Biopharmaceuticals, Personnel

The Carlyle Group Agrees to Acquire Johnson and Johnson’s Ortho-Clinical Diagnostics for $4.15 Billion

Thu, 01/16/2014 - 15:26
Healthcare Screening, Diagnosis and Monitoring Company Is Poised for Accelerated Product Innovation and Growth NEW YORK--(Healthcare Sales & Marketing Network)--Global alternative asset manager The Carlyle Group (CG) has agreed to acquire Johnson & John...
Diagnostics, Mergers & Acquisitions
The Carlyle Group, Johnson & Johnson, Ortho-Clinical Diagnostics

Johnson and Johnson Announces Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics

Thu, 01/16/2014 - 15:23
NEW BRUNSWICK, N.J., Jan. 16, 2014 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson (JNJ) today announced that it has received a binding offer from The Carlyle Group to acquire its Ortho-Clinical Diagnostics business for $4.15 Billion. &q...
Diagnostics, Mergers & Acquisitions
Johnson & Johnson, Ortho-Clinical Diagnostics, The Carlyle Group

Federal Jury Finds Medtronic CoreValve Willfully Infringes Edwards' Transcatheter Valve Patent

Wed, 01/15/2014 - 21:18
IRVINE, CA--(Healthcare Sales & Marketing Network) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that a federal jury today found that Edwards' United States Cribier tra...
Devices, Interventional Cardiology, Litigation
Edwards Lifesciences, Medtronic, CoreValve, Transcatheter Aortic Valve

Medtronic to Appeal Federal District Court Verdict

Wed, 01/15/2014 - 16:24
MINNEAPOLIS - Jan. 15, 2014 -- (Healthcare Sales & Marketing Network) -- A jury in the Federal District Court of Delaware today decided in favor of Edwards Lifesciences, ruling that the Medtronic (MDT) CoreValve® System infringed on Edward`s Cribier p...
Devices, Interventional Cardiology, Litigation
Medtronic, Edwards Lifesciences, CoreValve, Transcatheter Aortic Valve

Competitive Tech's Calmare(R) Pain Device Therapy Garners Favorable Medicare Coverage Judgment

Wed, 01/15/2014 - 16:20
Ruling Appeal Establishes Calmare Treatments a "Medical Necessity" In Cancer-Related Chemotherapy Pain Case FAIRFIELD, Conn., Jan. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Competitive Technologies, Inc., (CTTC) (CTI), a biotechno...
Devices, Reimbursement
Competitive Technologies, Calmare, pain therapy

Varian Medical Systems Receives FDA 510(k) Clearance for its ProBeam(TM) Proton Therapy System

Wed, 01/15/2014 - 16:15
PALO ALTO, Calif., Jan. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (VAR) has received FDA 510(k) clearance for its updated ProBeam™ proton therapy system. Varian's ProBeam system gives clinicians options for delivering...
Devices, Oncology, FDA
Varian Medical Systems, ProBeam, proton therapy, radiotherapy

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.

Wed, 01/15/2014 - 16:13
LAVAL, Quebec , Jan. 15, 2014 (Healthcare Sales & Marketing Network) - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("...
Biopharmaceuticals, Devices, Mergers & Acquisitions
Valeant Pharmaceuticals, Solta Medical, Fraxel

AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer

Wed, 01/15/2014 - 12:15
Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan. 15, 2014 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV) today announced the initiation of a Phase 3 clinical tr...
Biopharmaceuticals, Oncology
AbbVie, veliparib, ABT-888, carboplatin, breast cancer

Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children

Wed, 01/15/2014 - 12:06
OTREXUP provides a new option that may benefit patients when the response to oral methotrexate is inadequate EWING, N.J.--(Healthcare Sales & Marketing Network)--Antares Pharma, Inc. (ATRS) today announced the availability of OTREXUP™, the first U.S. Fo...
Biopharmaceuticals, Drug Delivery, Product Launch
Antares Pharma, OTREXUP, methotrexate, rheumatoid arthritis

Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products

Tue, 01/14/2014 - 15:36
Commercial launch into this $500 million market, along with its drug candidate for the treatment of diabetic foot ulcers, underscores company’s commitment to regenerative medicine PRINCETON, N.J.--(Healthcare Sales & Marketing Network)--Derma Sciences, ...
Devices, Wound Care, Licensing
Derma Sciences, BioD LLC, Skin Substitute, Amniotic Membrane

Neuralstem Appoints Catherine Angell Sohn To Board Of Directors

Tue, 01/14/2014 - 15:32
ROCKVILLE, Md., Jan. 14, 2014 -- (Healthcare Sales & Marketing Network) -- Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board of Directors, bringing the total number of board me...
Regenerative Medicine, Neurology, Personnel
Neuralstem, neural stem cell, stem cell

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong